

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Cetuximab for metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed: Provisional matrix of consultees and commentators sent for consultation				
Summary of comments, action taken, and justification of action:				
	<i>Proposal:</i>	<i>Proposal made by:</i>	<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Cetuximab for metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)

Issue date: July 2008

1.	It would seem appropriate for both the British Oncology Pharmacists Association (BOPA) and for King's College Hospital Maxillofacial Unit to be included as consultees.	Merck Serono	Added	<i>These organisations interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore both the British Oncology Pharmacists Association (BOPA) and for King's College Hospital Maxillofacial Unit have been added to the matrix.</i>
2.	Suggestion that the Afiya Trust and the British Ethnic Health Awareness Foundation (BEHAF) should be included as consultees	PPIP	Added	<i>These organisations interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore both the Afiya Trust and the British Ethnic Health Awareness Foundation (BEHAF) have been added to the 'patient' section of the matrix.</i>

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Cetuximab for metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)

Issue date: July 2008

3.	Suggestion that the Brain and Spine Foundation should be included as consultees.	PPIP		<p><i>Added</i></p> <p><i>This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the Brain and Spine Foundation has been added to the 'patient' section of the matrix</i></p>
4.	Suggestion that the Cancer Laryngectomee Trust should be included as consultees.	PPIP		<p><i>Added</i></p> <p><i>This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the Cancer Laryngectomee Trust has been added to the 'patient' section of the matrix</i></p>

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Cetuximab for metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)

Issue date: July 2008

5.	Suggestion that Changing Faces should be included as consultees	PPIP	<i>Added</i>	<i>This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore Changing Faces has been added to the 'patient' section of the matrix</i>
----	---	------	--------------	--

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of Cetuximab for metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)

Issue date: July 2008